Takeda Pharmaceutical (NYSE:TAK) Sees Large Volume Increase – Here’s Why

Shares of Takeda Pharmaceutical Co. (NYSE:TAK) saw unusually-high trading volume on Thursday . Approximately 2,221,099 shares traded hands during trading, a decline of 26% from the previous session’s volume of 3,017,695 shares.The stock last traded at $16.5850 and had previously closed at $16.45.

Analysts Set New Price Targets

TAK has been the subject of several recent analyst reports. Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Finally, Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Takeda Pharmaceutical Price Performance

The stock has a market capitalization of $54.59 billion, a PE ratio of 43.98 and a beta of -0.07. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60. The stock’s fifty day moving average is $16.12 and its 200-day moving average is $16.97.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The company had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. As a group, equities analysts predict that Takeda Pharmaceutical Co. will post 1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Large investors have recently made changes to their positions in the stock. Capital Research Global Investors grew its stake in shares of Takeda Pharmaceutical by 0.6% in the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after buying an additional 82,643 shares during the period. UBS Group AG raised its position in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after buying an additional 1,869,323 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after buying an additional 2,854,069 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after acquiring an additional 692,404 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Takeda Pharmaceutical by 14.2% in the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after acquiring an additional 370,800 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.